Ergoteles LLC Intra Cellular Therapies, Inc. Transaction History

Ergoteles LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$43.8 - $56.99 $387,279 - $503,905	8,842 New	8,842 $478,000
Q3 2022 Nov 14, 2022	BUY	$42.7 - $59.99 $519,872 - $730,378	12,175 Added 341.32%	15,742 $732,000
Q2 2022 Aug 12, 2022	BUY	$43.0 - $65.64 $153,381 - $234,137	3,567 New	3,567 $204,000
Q1 2022 May 13, 2022	SELL	$38.74 - $62.09 $2.08 Million - $3.33 Million	-53,656 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$35.2 - $53.42 $1.49 Million - $2.26 Million	42,256 Added 370.67%	53,656 $2.81 Million
Q3 2021 Nov 15, 2021	BUY	$28.72 - $42.49 $327,408 - $484,386	11,400 New	11,400 $425,000
Q1 2021 May 12, 2021	SELL	$30.8 - $39.51 $446,600 - $572,895	-14,500 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$23.34 - $32.22 $338,430 - $467,190	14,500 New	14,500 $461,000

406

89M

264K

129K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $12.1B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.